Craig… how could you be more wrong? A scratch off lottery
Craig… how could you be more wrong? A scratch off lottery ticket? Really?
Just HIV Combo and mTNBC shows you that trials have proved by the science that we will have future approvals. It’s not a matter of if… it’s a matter of when.
The only real dispute is when… HIV Combo is a minimum of 9 months if we were to file in May. So next year for a BLA. But that’s best case scenario.
As for mTNBC… we have another phase 3 trial coming now with a phase two that was equal to or slightly better than Trodelvy as the standard of care. This also is not a IF… but a when. The issue with that… is it could be next year also since we missed the boat on the BTD per SK.
So don’t give us a lottery presumptive prediction when it’s not a matter of IF. As long as we keep our funding going we will get there. This much is almost guaranteed by real results. Tell me I am wrong… tell me these two indications won’t prove out and why they won’t. Of coarse there is a properly filled out BLA that needs to happen. Do you think we will hire another rogue CRO that doesn’t have the experience we need? I don’t think so…
We haven’t even mentioned Nash and that could still get a BTD or if not we continue on in a phase 3 trial in what is expected to have great results to prove our drug too.
At any point we could get lucky and find another partner besides Vyera/Regnum to help us get over the finish line. I am not a big believer of this but the CC said we are in NDA’s and anything is possible.
All I know is our class of employees of Cytodyn has improved dramatically since I have been invested. We have had an improvement by leaps and bounds in our BOD. Our scientific board represents almost all our pending indications we are looking at and mostly PHD’s in each indication. We are building a machine if you take a step back and look at where we are… compared to where we were just 2 or even 3 years ago. Things change as time goes on and we have really upped our game all around. So… tell me why we are a lottery ticket at best again…
7
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...
Continue Reading
Revenue Growth, Yet the Road Is Rocky Buckle up, investors, because Zepp Health Corporation's (NYSE: ZEPP) latest financials are a bit of a mixed salad—there's some good and some bad tossed in. Reporting a revenue of $63.5 million for the second quarter of 2026, the company managed to eke out a 6.9% increase year-over-year. But before you pop the champagne, let's dig a...
Continue Reading
Next-Gen Screens: Breakthrough or Bust? So, Acer’s stepping up its game, unveiling an armory of gadgets designed to cement their spot in the tech arena. On the menu today? ePaper displays and enhanced connectivity gizmos that could either tip the scales or sink like a stone. Keep your eyes peeled, though—these updates aren't just another throwaway press release....
Continue Reading
Cracking the Challenger Code: BOC Group's Debut Ever heard of BOC Group? If you haven’t, it’s time to pay attention. This Dublin-based outfit just muscled its way into the Challenger Quadrant of the 2026 Gartner Magic Quadrant for Digital Twin of an Organization Platforms. Not bad for its first trip to the dance. When a company crashes the scene like this, eyebrows...
Continue Reading
New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...
Continue Reading
Unraveling the Volato Merger Drama Boy, the plot thickens with Volato Group, Inc. (SOAR), and it ain’t the first time we’ve seen this kind of shuffle in the market. Now, Volato’s got itself tangled up with Alignment Engine Inc. through a proposed merger. Sounds routine at first; we all know mergers are part of the corporate game. But here's the twist—shareholders...
Continue Reading
Embracing Tradition with a Modern Twist Well, here's to new beginnings wrapped in old flavors, folks. September 1, 2026, marks the arrival of Kareem's Lebanese Kitchen at Rio Lakefront in Gaithersburg, Maryland. It's where the Mediterranean meets the Chesapeake in an unexpected culinary celebration. Chef Rachid Eido's Legacy Third-generation Lebanese Chef Rachid Eido is...
Continue Reading
Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...
Continue Reading
Kroger Welcomes a Seasoned Retail Veteran Change often arrives with the dawn of new leadership. As Kroger takes a page from the playbook of large-scale retail transformation, they've enlisted Mark Ibbotson. Effective September 14, Ibbotson will step in as Executive Vice President and Chief Store Operations Officer. It's a roll of the dice that could either accelerate...
Continue Reading
Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...
Continue Reading
Top 5 Most Recently Viewed Articles
ABN AMRO's Share Buyback Program Progress Overview ABN AMRO has recently reported significant advancements regarding its EUR 250 million share buyback program that was announced earlier in the month. This initiative aims to bolster shareholders' value and demonstrate the bank's commitment to enhancing its financial position. Transaction Details and Financial Insights...
Continue Reading
What Recent Options Trades Say About Robinhood Markets Investors are leaning bearish on Robinhood Markets, and the options tape shows it. Recent flow highlights how larger traders are setting up, offering a clear read on sentiment without guessing at motives. Breaking Down the Recent Trades In our review of options activity for Robinhood Markets (NASDAQ: HOOD), we counted...
Continue Reading
Neuronetics Amends Registration Rights Agreement Neuronetics, Inc. (NASDAQ: STIM), a pioneering medical technology firm, has recently made significant changes to its Registration Rights Agreement with Madryn Asset Management LP. This amendment extends the period for Madryn to demand the registration of their acquired shares, increasing the Demand Registration Period from...
Continue Reading
Insights into Macy's Recent Performance Macy’s Inc (NYSE: M) has recently revealed its sales dynamics, indicating that even during a period of stronger financial results, its stock took a slight dip. Despite a notable improvement in sales, profit, and comparable growth metrics, the market response has been tempered, reflecting complex customer behaviors ahead of the...
Continue Reading
Celebrating Steward Partners' Remarkable Forbes Recognition Top honors reflect exceptional service, teamwork, and commitment to excellence Steward Partners, a thriving independent financial services firm known for its employee-owned model, recently celebrated a significant achievement. The firm proudly announced that seven of its partners have been recognized in the...
Continue Reading